Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
R Flisiak, D Zarębska-Michaluk, M Rogalska… - Pharmacological …, 2022 - Springer
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Early access to oral antivirals in high-risk outpatients: good weapons to fight COVID-19
G Bruno, M Giotta, S Perelli, G De Vita, N Bartolomeo… - Viruses, 2022 - mdpi.com
Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …
[HTML][HTML] Effectiveness of oseltamivir in reducing COVID-19-related in-hospital deaths: A pharmacoepidemiological study
Background Oseltamivir is a low-cost antiviral agent that could support or complement
treatment of COVID-19. This study assessed whether oseltamivir is effective in reducing …
treatment of COVID-19. This study assessed whether oseltamivir is effective in reducing …
Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The …
JJ Petersen, CK Jørgensen, P Faltermeier, F Siddiqui… - BMJ open, 2023 - bmjopen.bmj.com
Objectives To assess the effects of interventions authorised by the European Medicines
Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 …
Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 …
Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …
[HTML][HTML] The effect of molnupiravir on post-acute outcome of COVID-19 survivors
We read with great interest the review article by Gary et al., in which they raised several
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19
RL Atmar, N Finch - Antimicrobial agents and chemotherapy, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …
Characteristics and outcomes of US veterans with immunocompromised conditions at high risk of SARS-CoV-2 infection with or without receipt of oral antiviral agents
CA Gentry, PN Nguyen, SK Thind… - Clinical Infectious …, 2024 - academic.oup.com
Objectives Molnupiravir and nirmatrelvir-ritonavir were the first oral antiviral agents to
demonstrate reduced hospitalization or death in patients with severe acute respiratory …
demonstrate reduced hospitalization or death in patients with severe acute respiratory …